TABLE OF CONTENTS
|
| October 2018 Volume 17, Issue 10 |
 | | |
 |  Comment
News and Analysis
Research Highlights
Perspectives
Reviews
Erratum
| |
| Advertisement |
 |
| |
|
| |
Comment | |
|
Genome editing to 're-write' wrongs
Mary Ellen Perry, Kayla M. Valdes, Elizabeth Wilder, Christopher P. Austin & Philip J. Brooks
pp689 - 690 | doi:10.1038/nrd.2018.91
The NIH has launched the Somatic Cell Genome Editing (SCGE) programme to accelerate the development of safer and more effective genome-editing therapeutics.
Full Text | PDF
Collection: Genome Editing
|
News and Analysis | |
|
Microfluidics platform lowers barrier to drug combination screening
Asher Mullard
pp691 - 692 | doi:10.1038/nrd.2018.161
Nanodroplets promise to reduce the equipment, cost and time constraints of high-throughput screening, if researchers can overcome long-standing hurdles.
Full Text | PDF
|
Malaria medicine box expands
Asher Mullard
pp693 - 695 | doi:10.1038/nrd.2018.156
With the FDA's approval of GlaxoSmithKline's tafenoquine, global health experts will at last have access to a long-awaited new treatment for Plasmodium vivax recurrence. Much-needed novel treatments for the more common Plasmodium falciparum are in phase II trials.
Full Text | PDF
|
|
| News in Brief |
|
Industry advances landmark CRISPR candidate into the clinic
Asher Mullard
p697 | doi:10.1038/nrd.2018.175
Full Text | PDF
|
Chi-Med scores key approval for 'discovered in China' cancer drug
Asher Mullard
p697 | doi:10.1038/nrd.2018.176
Full Text | PDF
|
Painkilling anti-NGF antibodies stage phase III comeback
Asher Mullard
p697 | doi:10.1038/nrd.2018.177
Full Text | PDF
|
|
| Biobusiness Briefs |
|
Trial watch: Burgeoning oncology pipeline raises questions about sustainability
Jon Moser & Paul Verdin
pp698 - 699 | doi:10.1038/nrd.2018.165
Full Text | PDF
|
Market watch: Upcoming market catalysts in Q4 2018
Stephanie Arthan
p699 | doi:10.1038/nrd.2018.162
Full Text | PDF
|
|
| An Audience With |
|
Ida Sim
pp700 - 701 | doi:10.1038/nrd.2018.178
Ida Sim, Vivli co-founder and UCSF informatician, discusses the need for a neutral broker platform that can facilitate access to and analysis of industry and academic patient-level clinical trial data.
Full Text | PDF
|
|
| From the analyst's couch |
|
Trends driving clinical trials into large clinical care settings
Kenneth Getz
pp703 - 704 | doi:10.1038/nrd.2018.111
This analysis highlights data indicating the limitations of traditional clinical trial processes, and discusses how moving clinical trials into large clinical care settings could help meet the growing demands for large volumes of sophisticated patient data.
Full Text | PDF
Collection: Cancer at Nature Research
|
Research Highlights | |
|
| |
|
 |
Perspectives | |
|
|
| Opinion |
|
Expanding the medicinal chemistry synthetic toolbox
Jonas Boström, Dean G. Brown, Robert J. Young & György M. Keserü
pp709 - 727 | doi:10.1038/nrd.2018.116
Analysis of the role of synthetic organic chemistry in the identification of chemical starting points for drug discovery and subsequent optimization into candidate drugs indicates that a small number of reactions and commercially available building blocks dominate. This Perspective highlights opportunities for expanding the synthetic toolbox of medicinal chemists, potentially enabling the more effective exploration of therapeutically relevant chemical space.
Full Text | PDF
|
Reviews | |
|
Therapeutic approaches to Huntington disease: from the bench to the clinic
Nicholas S. Caron, E. Ray Dorsey & Michael R. Hayden
pp729 - 750 | doi:10.1038/nrd.2018.133
New therapies, including RNA-based and gene therapies, are poised to change the therapeutic landscape for Huntington disease. In this article, Hayden and colleagues review the progress that has been made in the past 25 years in developing therapies for this disease and highlight the pitfalls and potential of future treatments.
Full Text | PDF
|
An RNA toolbox for cancer immunotherapy
Fernando Pastor, Pedro Berraondo, Iñaki Etxeberria, Josh Frederick, Ugur Sahin et al.
pp751 - 767 | doi:10.1038/nrd.2018.132
In this Review, Pastor et al. provide an overview of RNA-based agents used in cancer immunotherapy — ranging from RNA vaccines encoding cancer neoantigens to interference RNAs and protein-binding RNA aptamers — providing insights into this emerging field.
Full Text | PDF
Collection: Cancer at Nature Research
|
Erratum | |
|
Gene therapy for neurological disorders: progress and prospects
Benjamin E. Deverman, Bernard M. Ravina, Krystof S. Bankiewicz, Steven M. Paul & Dinah W. Y. Sah
p767 | doi:10.1038/nrd.2018.158
Full Text | PDF
|
| Advertisement |
|
Nature Briefing is an essential round-up of science news, opinion and analysis, free in your inbox every weekday. With Nature Briefing, we'll keep you updated on the latest research, so you can focus on yours.
Click here to sign up. |  | | |
|
| |
| | | | | | Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com | | | | | | |
|
No comments:
Post a Comment